2nd edition. T The Compendium has been developed as a clear and concise instrument to facilitate the understanding and planning of delivery of high-quality care for everybody affected by TB. It incorporates all recent policy guidance from WHO; follows the care pathway of persons with signs or symptoms of TB in seeking diagnosis, treatment and care; and includes key algorithms and cross-cutting elements that are essential to a patient-centered approach in the cascade of TB care. The Compendium is structured into 33 WHO standards and consolidates all current WHO TB policy recommendations into a single resource, with electronic links to the individual, comprehensive WHO policy guideline

A practical tool to help health workers in the clinical and operational management of multidrug-resistant tuberculosis with special focus on the introduction, implementation and management of the nine-month treatment regimen

The new, all oral, 20-month MDR-TB regimens range from US $1,600* (using bedaquiline and linezolid for 6 months and levofloxacin as the fluoroquinolone) to US $2,100* (using linezolid for 12 months and moxifloxacin as the fluoroquinolone

The first important change is a new priority ranking of the available medicines for MDR-TB treatment, based on a careful balance between expected benefits and harms. Treatment success for MDR-TB is currently low in many countries. This could be increased by improving access to the highest-ranked medicines for all patients with MDR-TB.

Stop TB`s GDF provides a wide range of diagnostic equipment and laboratory supplies in its Diagnostics Catalog

Assurer des prestations optimales dans la chaîne de soins destinés aux patients tuberculeux Deuxième édition - Juin 2018

The new WHO recommendations for the treatment of isoniazid-resistant, rifampicin-susceptible TB are based upon a review of evidence from patients treated with such regimens by a Guideline Development Group in conformity with WHO requirements for evidence-based policies

Considerando los cambios estratégicos en el abordaje de la salud pública y de la atención primaria de la salud, la prevención y el control de la tuberculosis en Ecuador genera un cambio en la parte organizacional y en la prestación de servicios con enfoque en grupos vulnerables y/o con factores de riesgo acorde a los ciclos de vida. Esta documento contempla una orientación apoyada en evidencia científica y otras recomendaciones en la práctica médica, basadas en el buen juicio clínico de quien la emplea como referencia, en las necesidades del afectado y en los recursos disponibles al momento de la atención, dando prioridad a la prevención, diagnóstico, tratamiento y control de la TB

Version: 24 April 2018